Abstract
The synthesis and structure-activity relationship of a series of 6-substituted picolinamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1 are described. The optimization of the left-hand side of lead compound 1 resulted in the discovery of the highly potent, selective, and orally available inhibitor 24, which demonstrated an excellent activity in a mouse ex vivo pharmacodynamic model. Moreover, compound 24 reduced the blood glucose and improved the lipid profiles in ob/ob mice after oral administration.
Keywords:
11β-HSD1 inhibitor; Diabetes; Hyperlipidemia; Metabolic syndrome; Picolinamide.
Copyright © 2015 Elsevier Ltd. All rights reserved.
MeSH terms
-
11-beta-Hydroxysteroid Dehydrogenase Type 1 / antagonists & inhibitors
-
11-beta-Hydroxysteroid Dehydrogenase Type 1 / metabolism*
-
Administration, Oral
-
Amides / chemistry
-
Amides / pharmacokinetics
-
Amides / therapeutic use
-
Animals
-
Blood Glucose / analysis
-
Catalysis
-
Diabetes Mellitus, Experimental / drug therapy
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / therapeutic use
-
HEK293 Cells
-
Half-Life
-
Humans
-
Lipids / blood
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Mice, Obese
-
Palladium / chemistry
-
Picolinic Acids / chemistry*
-
Picolinic Acids / pharmacokinetics
-
Picolinic Acids / therapeutic use
-
Protein Binding
-
Structure-Activity Relationship
Substances
-
Amides
-
Blood Glucose
-
Enzyme Inhibitors
-
Lipids
-
Picolinic Acids
-
Palladium
-
11-beta-Hydroxysteroid Dehydrogenase Type 1
-
picolinamide